For many years neurotransmitters were a significant focus in neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. Still, the field has expanded and is now moving towards an approach focused on molecules (amyloid β, tau, α-synuclein) to understand the pathogenesis of the diseases and discover novel therapeutic targets. Amos Korczyn, MD, Tel Aviv University, Tev Aviv, Israel, discusses α-synuclein as a potential therapeutic target in Parkinson's disease. Prof. Korczyn explains that although alpha-synuclein is an excellent marker of the disease, it may not necessarily be a good therapeutic target. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.
